Samsung Biologics expands portfolio with organoids

Samsung Biologics said Monday it launched a drug candidate screening service to support clients in drug discovery and development, expanding its portfolio beyond contract development and manufacturing of biologics to include contract research. According to the company, it launched Samsung Organoids, a drug screening service using organoids. By engaging with clients from the early stages of drug candidate discovery, the company aims to have clients locked into its services ranging from contract development to manufacturing and research. Organoids are 3D miniaturized organ models derived from stem cells or tissue cells, thus mimicking the structure, organization and some functions of human organs. They are gaining industry attention as tools for research and drug development as they offer a cost-effective alternative to traditional testing methods while providing up to 85 percent patient similarity. This enables faster and more precise assessment of a drug candidate’s efficacy and toxicity. Samsung Biologics will begin its organoid services by screening anti-cancer drug candidates usingWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times